Highlights of This Issue 6059

SPECIAL FEATURES

CCR Translations

6061 Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed
Dung T. Le and Elizabeth M. Jaffee
See related article, p. 6286

6064 Test-Firing Ammunition for Spliceosome Inhibition in Cancer
Scott M. Dehm
See related article, p. 6296

CCR Perspectives in Drug Approval

6067 Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

Molecular Pathways

6074 Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer
Louise R. Howe, Kotha Subbaramaiah, Clifford A. Hudis, and Andrew J. Dannenberg

6084 Molecular Pathways: Induction of Polyploidy as a Novel Differentiation Therapy for Leukemia
Diane S. Krause and John D. Crispino

Review

6089 Lessons Learned from Radiation Oncology Clinical Trials
Fei-Fei Liu, for the workshop participants, Paul Okunieff, Eric J. Bernhard, Helen B. Stone, Stephen Yoo, C. Norman Coleman, Bhadravasi Vikram, Martin Brown, John Buatti, and Chandan Guha
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6205</td>
<td>Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model</td>
<td>Andressa Ardiani, Benedetto Farsaci, Connie J. Rogers, Andy Protter, Zhimin Guo, Thomas H. King, David Apelian, and James W. Hodge</td>
</tr>
<tr>
<td>6219</td>
<td>Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models</td>
<td>Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowska, Aik Choon Tan, Martine C. McManus, Anna Sperecho, Maria I. Kachaeva, Heather M. Selby, John J. Tentler, S. Gail Eckhardt, and Stephen Leong</td>
</tr>
<tr>
<td>6230</td>
<td>JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease</td>
<td>Emeline Evrot, Nicolas Ebel, Vincent Romanet, Claudia Roelli, Rita Andraos, Zhiyan Qian, Arno Dölemeyer, Ernesta Dannamaa, Dario Sterker, Robert Cozens, Francesco Hofmann, Masato Murakami, Fabienne Buffert, and Thomas Radimerski</td>
</tr>
<tr>
<td>6242</td>
<td>Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma</td>
<td>Yumeng Hua, Shai White-Gilbertson, Joshua Kellner, Saleh Rachidi, Saad Z. Usmani, Gabriela Chiosis, Ronald DePinho, Zihai Li, and Bei Liu</td>
</tr>
<tr>
<td>6252</td>
<td>Associations between Single-Nucleotide Polymorphisms in the PI3K-PTEN-akt-mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non-Small Cell Lung Cancer</td>
<td>Qianxia Li, Ju Yang, Qianqian Yu, Huanlei Wu, Bo Liu, Huihua Xiong, Guangyuan Hu, Jing Zhao, Xianlin Yuan, and Zhongxing Xiao</td>
</tr>
<tr>
<td>6261</td>
<td>Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma</td>
<td>Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Juyu Fujimoto, M. Gabriela Raso, Lorenzo Spaggiari, Domenico Galleta, Rohyn Riley, Elisha Hughes, Julia Reid, Zaina Sangale, Steven G. Swisher, Neda Kalhor, Cesar A. Moran, Alexander Gustin, Jerry S. Lynchburn, Massimo Barberis, and Edward S. Kim</td>
</tr>
</tbody>
</table>
CANCER THERAPY: CLINICAL

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O’Brien, Adelaida Piera, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, José Baselga, and Josep Tabernero

See related article, p. 6064

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O’Brien, Adelaida Piera, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, José Baselga, and Josep Tabernero

See related article, p. 6064

Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study


LETTERS TO THE EDITOR

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter


Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response

Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, and Dirk Schadendorf

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia

Mauricio Burotto, Maryalice Stetler-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, and Robert J. Kreitman

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia

Mauricio Burotto, Maryalice Stetler-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, and Robert J. Kreitman
ABOUT THE COVER

Cellular internalization of siRNA (red fluorescence) delivered by the nanocarrier (green fluorescence) specifically targeted to cancer cells. Superimposition of red (siRNA) and green (nanocarrier) fluorescence images gives yellow color. For details, see the article by Shah and colleagues on page 6193 of this issue.